



Chimerix, Inc.  
Investor Relations Department  
2505 Meridian Pkwy  
Suite 100  
Durham, NC 27713  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: CMRX**

Last Trade: 4.66

Trade Time: 2:33 PM ET  
May 23, 2017

Change: -0.06 ↓ (-1.168%)

Day Range 4.62 - 4.73

52-Week Range 3.50 - 6.64

Volume 101,877


Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*May 9, 2017*

[Chimerix Announces First Quarter 2017 Financial Results](#)

*May 2, 2017*

[Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017](#)

*Apr 20, 2017*

[Chimerix to Host Annual Investor Update on April 27, 2017](#)

*Mar 2, 2017*

[Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results](#)

*Feb 28, 2017*

[Chimerix to Present at Cowen and Company 37th Annual Health Care Conference](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 2, 2017*

[Annual Report \(10-K\)](#)

*May 1, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 7, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2016*

[Quarterly Report \(10-Q\)](#)